Ieq Capital LLC holds a $21.12 million stake in Johnson & Johnson (NYSE: JNJ)
Ieq Capital LLC increased its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 9.4% in Q1, Holdings Channel.com reports. The company held 119,172 shares of the company after acquiring an additional 10,226 shares during the period. Ieq Capital LLC’s holdings in Johnson & Johnson were worth $21,121,000 when it last filed with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also bought and sold shares of JNJ. Family CFO Inc bought a new position in Johnson & Johnson in Q4 worth about $26,000. Steward Financial Group LLC bought a new position in Johnson & Johnson in Q4 valued at around $34,000. Joseph P. Lucia & Associates LLC bought a new position in Johnson & Johnson in Q1 worth approximately $38,000. Advocacy Wealth Management Services LLC increased its stake in Johnson & Johnson by 41.4% in the 1st quarter. Advocacy Wealth Management Services LLC now owns 229 shares of the company valued at $41,000 after purchasing an additional 67 shares during the period. Finally, Gibson Wealth Advisors LLC bought a new position in Johnson & Johnson in Q4 valued at around $49,000. Institutional investors and hedge funds own 68.78% of the company’s shares.
Johnson & Johnson trades up 1.5%
JNJ opened at $178.23 on Friday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt ratio of 0.39, a current ratio of 1.39 and a quick ratio of 1.14. The company has a market capitalization of $468.99 billion, a price-earnings ratio of 24.02, a PEG ratio of 3.49 and a beta of 0.63. The company’s 50-day moving average price is $176.76 and its two-hundred-day moving average price is $174.33.
Johnson & Johnson (NYSE:JNJ – Get Rating) last reported results on Tuesday, April 19. The company reported earnings per share of $2.67 for the quarter, beating analyst consensus estimates of $2.60 by $0.07. The company posted revenue of $23.43 billion for the quarter, versus analyst estimates of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. The Company’s revenue for the quarter increased 5.0% compared to the same quarter last year. During the same period a year earlier, the company posted EPS of $2.59. As a group, research analysts predict Johnson & Johnson will post earnings per share of 10.21 for the current year.
Johnson & Johnson increases its dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 7. Shareholders of record on Tuesday, May 24 received a dividend of $1.13. The ex-dividend date was Monday, May 23. This represents a dividend of $4.52 on an annualized basis and a dividend yield of 2.54%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s payout ratio is 60.92%.
Insider Trading at Johnson & Johnson
Separately, insider William Hait sold 29,699 shares of the company in a trade that took place on Thursday, April 21. The shares were sold at an average price of $183.58, for a total value of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares of the company, valued at approximately $14,729,724.88. The sale was disclosed in a filing with the Securities & Exchange Commission, accessible via the SEC’s website. Separately, CAO Robert J. Decker sold 8,462 shares of the company in a trade on Thursday, May 26. The shares were sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accountant now owns 15,473 shares of the company, valued at approximately $2,785,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, accessible via this hyperlink. Additionally, insider William Hait sold 29,699 shares of the company in a trade on Thursday, April 21. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the transaction, the insider now owns 80,236 shares of the company, valued at approximately $14,729,724.88. The disclosure of this sale can be found here. In the past 90 days, insiders have sold 78,161 shares of the company worth $13,895,302. Insiders of the company own 0.35% of the shares of the company.
Analysts set new price targets
Several equity research analysts have recently released reports on the stock. Morgan Stanley raised its price target on Johnson & Johnson shares from $173.00 to $174.00 and gave the company an “equal weight” rating in a Friday, July 8 report. Daiwa Capital Markets assumed coverage for Johnson & Johnson shares in a Wednesday, June 22 report. They set an “outperformance” rating on the stock. Citigroup lowered its price target on Johnson & Johnson shares from $210.00 to $205.00 in a Tuesday, May 17 report. Wells Fargo & Company raised its price target on Johnson & Johnson shares from $190.00 to $195.00 and gave the company an “overweight” rating in a report released Wednesday. Finally, StockNews.com upgraded Johnson & Johnson shares from a “buy” rating to a “strong buy” rating in a Tuesday, May 17 report. Four analysts gave the stock a hold rating, six gave the stock a buy rating and one gave the stock a strong buy rating. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $191.29.
About Johnson & Johnson
(Get an evaluation)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures and sells various healthcare products worldwide. The Company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the brands AVEENO, CLEAN & CLEAR, DR.
Want to see what other hedge funds own JNJ? Visit HoldingsChannel.com for the latest 13F filings and insider trading for Johnson & Johnson (NYSE:JNJ – Get Rating).
Get news and reviews for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily newsletter.
Comments are closed.